IPSEN 2020 Integrated Annual report

Focus.Together.
For patients and society.

Scroll to explore

An Interview with David Loew
Chief Executive Officer

David Loew became Ipsen’s Chief Executive Officer in July 2020, bringing with him nearly 30 years of leadership and experience across a range of therapeutic areas. Here, he reflects on the unprecedented events of the past year and what lies ahead for Ipsen.

David Loew presents the new Group strategy 
David Loew presents the new Group strategy 

What is it about Ipsen that made you want to join?

I felt great enthusiasm for Ipsen’s position and potential. Despite the challenges we will face in the near future with generics competition against Somatuline® (lanreotide), I see growth potential that we can unlock within our pipeline and on other brands, as well as additional external opportunities we can tap into with our existing firepower. Ipsen is well positioned to amplify its positive impact for all involved: patients, employees, society and shareholders.

READ THE FULL INTERVIEW
“I see growth potential that we can unlock within our pipeline and on other brands, as well as additional external opportunities we can tap into with our existing firepower.”
David Loew — Chief Executive Officer

FOR PATIENTS &
FOR SOCIETY

For patients

Patients are the heart of everything we do.
Our focus on the fields of Oncology, Rare Disease and Neuroscience enables us to develop an ever-greater understanding of patients’ needs and experiences. In 2020, despite difficulties due to COVID-19-induced lockdowns, Ipsen increased efforts to support and maintain an open dialogue with patient organizations.

For society

Ipsen has a responsibility to society and this was never more evident than in 2020. We responded to an unprecedented year by redoubling our efforts to support patients, communities and the planet.

A NEW STRATEGY
FOR A NEW ERA OF IPSEN

For the short and long term

Under the overarching theme of Focus. Together. For patients & society, Ipsen will be focusing on four strategic priorities to accelerate our innovation and drive positive impact for patients, employees, shareholders and society - a strategy for the short and long term.

Focus.
Together.
For patients
and society.

OUR COMMITMENTS

Ipsen’s priority is to improve the lives of patients, their caregivers, their communities and, ultimately, society. We leverage our existing assets and seek opportunities to go further and reach more patients, advocacy groups and healthcare providers. We consider the entire experience of illness and treatment, in order to pinpoint areas of unmet need. We know every patient is unique and requires their own support system. We are honored to be a part of the journey for patients and caregivers.

Creating value for patients, society, and all stakeholders

Our assets and resources contribute to the sustainability of our business model, which is based on a strong ethical culture. Our value-creation model demonstrates the positive outcomes of our vital work for patients, employees and society.

READ MORE

Partnering with stakeholders to create
long-term value

To ensure the best possible patient outcomes, we work with all stakeholders to develop strategies, make decisions and achieve our ambitions.

READ MORE

CSR at the heart of our strategy

“Our Company Social Responsibility approach—based on the three pillars, employees, communities and the environment—is fully embedded in our strategy, contributing to the sustainability of our business model and based on a strong ethical culture. By working with all stakeholders I am convinced we can move mountains to have a positive impact for patients and society. At Ipsen, we are all inspired to achieve this together.” David Loew, CEO of Ipsen

READ MORE

Employees: embodying our company values

Our employees are fundamental to the value we provide for patients, society and the environment. Throughout a particularly challenging 2020, we continued to focus on the primary goals of keeping our people safe, enabling them to grow and improving the employee experience.

READ MORE
Creating value for patients, society, and all stakeholders
Partnering with stakeholders to create
long-term value
CSR at the heart of our strategy
Employees: embodying our company values

2020 Highlights

14 January
11 March
March
1 April
4 May
28 May
8 June
17 June
2 July
25 August
2 September
14 September
19 September
25 September
7-11 October
22 October
30 November
1 December

14 Jan

Ipsen appoints Steven Hildemann, MD, PhD as Executive Vice President, Chief Medical Officer and Head of Global Medical Affairs and Pharmacovigilance, effective 1 March 2020.

11 Mar

Ipsen presents data at the ENETS Annual Conference 2020 which highlights new insights into the treatment of neuroendocrine tumors (NETs) and acromegaly. The presentation includes quantitative findings from patients and healthcare professionals.

March

The Shingo Institute awards a gold medal prize for manufacturing excellence to Ipsen’s manufacturing site in Signes (France).

1 Apr

Ipsen donates €2 million to the Institut Pasteur to support their COVID-19 research efforts.

4 May

Ipsen enters an option agreement with Canadian research commercialization center IRICoR and the Université de Montréal for the worldwide rights to a high-value oncology program.

28 May

Ipsen appoints David Loew as Chief Executive Officer, effective 1 July 2020.

8 Jun

We publish eight abstracts in the Journal of the Endocrine Society, including data from a first-of-its-kind study into the one-year natural progression of fibrodysplasia ossificans progressiva (FOP) and the impact of heterotopic ossification (HO) on patients’ physical mobility over time.

17 Jun

Ipsen receives FDA Fast Track designation for Onivyde® (liposomal irinotecan) as a first-line combination treatment for metastatic pancreatic cancer. Fast Track facilitates medicine development and gets these life-saving drugs to patients faster.

2 Jul

Ipsen joins a clinical collaboration with Exelixis and Roche to fund the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials to evaluate Cabometyx® (cabozantinib) in combination with atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer.

25 Aug

Ipsen's research scientists present the first-ever Phase III trial results for an investigational medicine for the prevention of HO for FOP at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting.

2 Sep

Ipsen appoints Patrice Zagame, Executive Vice President, Specialty Care International and Bartek Bednarz, Executive Vice President, Global Product & Portfolio Strategy to the Executive Leadership Team.

14 Sep

Ipsen showcases our commitment to patient-centric advances in oncology with a company-record 17 abstracts presented at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress, covering a wide-range of cancer types and therapies.

19 Sep

At the ESMO Virtual Congress, Ipsen announced the first presentation of results from the pivotal Phase III CheckMate-9ER clinical trial, in which Cabometyx® (cabozantinib) in combination with nivolumab demonstrated significant improvements across all efficacy endpoints, including overall survival, in previously untreated advanced renal cell carcinoma (RCC).

25 Sep

Ipsen appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020.

7-11 Oct

Ipsen's research scientists present 12 abstracts at the 11th World Congress for Neurorehabilitation (WCNR), taking place jointly with the 25th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER).

22 Oct

Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19.

30 Nov

Ipsen receives FDA Fast Track designation for Onivyde® as a second-line monotherapy treatment for small cell lung cancer (SCLC), allowing us to address another unmet medical need.

1 Dec

Ipsen unveils its new Group strategy: Focus. Together. For patients & society, with a focus on Oncology, Rare Disease and Neuroscience. We also reaffirm our commitment to R&D and our sustainable pipeline.

2020 KEY INDICATORS

Our key financial indicators

Despite the challenges of 2020, Ipsen came out stronger and more committed than ever to improving patients’ lives.

€2,592M

Ipsen sales

€829.3M

Core operating income

€405.6M

R&D investment

550+

employees working in R&D

4

global R&D hubs in Cambridge (US), Oxford (UK),
Paris-Saclay (France) & Shanghai (China)

20+

medicines in our portfolio

€356.1M

in Neuroscience sales

€1,969.8M

in Oncology sales

€210.6M

in consumer HealthCare sales

€55.2M

in Rare Disease sales

Beyond numbers

The value we create is not just measured through our financial figures. Fully dedicated to CSR, we are as proud of our non-financial indicators as we are of our financial results.

Explore our different non-financial indicators by theme:

  • EMPLOYEES
  • COMMUNITIES
  • ENVIRONMENT

13

countries where Ipsen is recognized as an Awarded Employer, up from seven in 2019

1,000

employees participated in Ipsen in Motion

140+

employees contributed insights, which led to the development of the new Ipsen Way of Being

90%

of women appointed to the Global Leadership Team (GLT) were promoted internally

42%

gender balance on the Global Leadership Team (GLT)

1,300+

employees in 30+ countries volunteered for our 2020 Community Day

210

patient advocacy groups collaborated with Ipsen globally in 2020

44,700+

students and healthcare professionals in 100+ countries received Institut Pasteur / Fondation Ipsen training

36,500+

listeners to Fondation Ipsen’s podcasts

32%

reduction of greenhouse gas emissions from 2016 to 2020

16%

reduction in energy consumption compared to 2016

45%

reduction of process waste

30%

reduction in water consumption

13

countries where Ipsen is recognized as an Awarded Employer, up from seven in 2019

1,000

employees participated in Ipsen in Motion

140+

employees contributed insights, which led to the development of the new Ipsen Way of Being

90%

of women appointed to the Global Leadership Team (GLT) were promoted internally

42%

gender balance on the Global Leadership Team (GLT)

1,300+

employees in 30+ countries volunteered for our 2020 Community Day

210

patient advocacy groups collaborated with Ipsen globally in 2020

44,700+

students and healthcare professionals in 100+ countries received Institut Pasteur / Fondation Ipsen training

36,500+

listeners to Fondation Ipsen’s podcasts

32%

reduction of greenhouse gas emissions from 2016 to 2020

16%

reduction in energy consumption compared to 2016

45%

reduction of process waste

30%

reduction in water consumption